including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
The annual global premier event in nuclear medicine and molecular imaging, the 2026 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), has officially kicked off.
View moreEurope Performs More Than 10 Million Nuclear Medicine Procedures a Year. Now It Wants an Access Strategy.
Radiopharma’s Next Wave of Phase 3 Trials Is Already Taking Shape
Psychiatry May Be Nuclear Medicine’s Next Great Frontier
The Best Radiopharmaceutical in the Lab May Not Be the One That Can Actually Scale
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
Telix Strikes $1.65 Billion Deal for ITM, Bringing Nearly the Entire Radiopharma Chain Under One Company
